반응식
[C:1]([C:5]1[N:6]=[C:7]([N:16]2[CH2:20][CH2:19][C:18]([F:22])([F:21])[CH2:17]2)[C:8]2[N:13]=[N:12][N:11]([CH2:14][CH3:15])[C:9]=2[N:10]=1)([CH3:4])([CH3:3])[CH3:2].C(C1N=C(N2CCC(F)(F)C2)C2N=NNC=2N=1)(C)(C)C.BrC[CH:45]1[CH2:50][CH2:49]C[CH2:47][CH2:46]1>>[C:1]([C:5]1[N:6]=[C:7]([N:16]2[CH2:20][CH2:19][C:18]([F:21])([F:22])[CH2:17]2)[C:8]2[N:13]=[N:12][N:11]([CH2:14][CH:15]3[CH2:49][CH2:50][CH2:45][CH2:46][CH2:47]3)[C:9]=2[N:10]=1)([CH3:2])([CH3:3])[CH3:4]참가 물질
4
실험 절차
In analogy to the procedure described for the synthesis of 5-tert-butyl-7-(3,3-difluoro-pyrrolidin-1-yl)-3-ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl-7-(3,3-difluoropyrrolidin-1-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine and (bromomethyl)cyclohexane and isolated as white solid (4.2 mg, 27%). MS (m/e): 379.5 (MH+).
출처 및 근거
- ORD 기록
- ord-2e783c8b5f2d4a7d95147a423ed06285
- 출처 데이터셋
- uspto-grants-2014_06
- 특허 번호
- US08741906B2
연결된 노트
불러오는 중…